But when are they going to manufacture the medical cannabis products though? Pnina refers to Bio Health Pharmaceuticals in the half yearly in her report (p.3 para. 3), as a manufacturer of pharmaceuticals, following from the 8th Feb ann. saying that “High quality Pharmaceutical and Nutraceutical manufacturing practices are available to Cann Global right now, rather than later.”
I’m not sure what manufacturing practices means.
Anyway, if you have a look at announcements from Bio Health’s owners, Dongfang Modern (ASX.DFM), it’s clear from three announcements this year that they don’t have pharmaceutical manufacturing facilities yet.
The 14/1/19 ann. says that “growth strategies include an expansion into manufacture of pharmaceutical grades”
https://www.asx.com.au/asxpdf/20190114/pdf/441v82sfn38snh.pdf28th Feb says “potentially diversify into manufacturing pharmaceutical grade products”
https://www.asx.com.au/asxpdf/20190301/pdf/4433wkjh8c4w6t.pdfand the AGM presentation today says that “The plan allows diversification into health food pharmaceuticals ....” (p.17)
https://www.asx.com.au/asxpdf/20190527/pdf/445dcq675k9ccn.pdf